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Background: Rapid diagnostic tests (RDTs) largely account for the scale-up of malaria diagnosis in endemic settings.
However, diversity in labelling including the instructions for use (IFU) limits their interchangeability and user-
friendliness. Uniform, easy to follow and consistent labelling, aligned with international standards and appropriate
for the level of the end user’s education and training, is crucial but a consolidated resource of information regarding
best practices for IFU and labelling of RDT devices, packaging and accessories is not available.
Methods: The Roll Back Malaria Partnership (RBM) commissioned the compilation of international standards and
regulatory documents and published literature containing specifications and/or recommendations for RDT design,
packaging and labelling of in vitro diagnostics (IVD) (which includes RDTs), complemented with a questionnaire
based survey of RDT manufacturers and implementers. A summary of desirable RDT labelling characteristics was
compiled, which was reviewed and discussed during a RBM Stakeholder consultation meeting and subsequently
amended and refined by a dedicated task force consisting of country programme implementers, experts in RDT
implementation, IVD regulatory experts and manufacturers.
Results: This process led to the development of consensus documents with a list of suggested terms and
abbreviations as well as specifications for labelling of box, device packaging, cassettes, buffer bottle and accessories
(lancets, alcohol swabs, transfer devices, desiccants). Emphasis was placed on durability (permanent printing or
water-resistant labels), legibility (font size, letter type), comprehension (use of symbols) and ease of reference
(e.g. place of labelling on the box or cassette packaging allowing quick oversight). A generic IFU template was
developed, comprising background information, a template for procedure and reading/interpretation, a selection of
appropriate references and a symbol key of internationally recognized symbols together with suggestions about
appropriate lay-out, style and readability.
Conclusions: The present document together with its additional files compiled proposes best practices in labelling
and IFU for malaria RDTs. It is expected that compliance with these best practices will increase harmonization
among the different malaria RDT products available on the market and improve their user-friendliness.
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Global malaria burden and importance of diagnostic
testing
As the global burden of malaria is decreasing, diagnostic
testing for malaria before starting treatment is crucial to
avoid overtreatment with anti-malarials and delayed
management of non-malaria febrile illnesses. To this
end, since 2010, the World Health Organization (WHO)
broadened its recommendations for parasitological con-
firmation of malaria diagnosis before treatment to all
age groups [1,2]. Furthermore, in 2012, the “‘T3: Test.
Treat. Track.” initiative called to scale-up diagnostic
testing, better target treatment and improve surveillance
systems [3].
Scale-up of malaria diagnosis has mainly been achieved
by rolling-out of RDTs
Case management treatment guidelines recommend diag-
nostic testing by use of quality light microscopy or alterna-
tively by quality rapid diagnostic tests (RDTs) [2]. RDTs are
instrument-free test devices (primarily a plastic cassette
that encloses a test strip) capable of providing results
within 30 minutes. They require minimal training and ex-
pertise compared to microscopy and can be performed by
less-skilled health workers [4,5]. In endemic settings, diag-
nosis of Plasmodium falciparum infections made by well-
performing RDTs has been shown to be equal or superior
to routine microscopy, and appears to be more cost-
effective than microscopy [6-10]. RDTs are largely account-
able for the scale-up of parasitological diagnosis [1,5,11].
Limitations of RDTs: variety of procedures, limited
user-friendliness
Despite their robustness and apparent simplicity, RDTs
have their limitations [12]. Surveys suggest there are cur-
rently at least 200 RDT products on the market [13,14],
which vary both in type and design of test device (shape
of cassette, number of wells), accessories (specimen
transfer devices, lancets) and procedure (specimen vol-
ume, numbers of buffer drops, reading time). In
addition, there are many differences in labelling and ter-
minology for the RDT box, device packaging, buffer bot-
tles and accessories [5]. This diversity contributes to the
limitations in terms of user-friendliness especially since
RDTs are often performed by less-skilled heath workers.
Such differences create challenges in terms of training
when operators are required to switch from one RDT
product to another. Problems with operating different
RDT products are particularly noted during the early
phases of RDT introduction at the country level [5].
Harmonization and enhanced user-friendliness of RDTs
Enhanced harmonization of malaria RDT characteristics is
expected to facilitate procurement and supply managementas well as to reduce training/re-training and supervision
when switching from one RDT product to another or when
two or more RDT products are concurrently used in a
country. In addition, it is expected to improve general ad-
herence to manufacturer’s recommended procedures and
reduce operational errors. Uniform, easy to follow and con-
sistent labelling and instructions for use (IFU) are crucial to
a good performance of the test and to harmonization of
RDTs [15], but a comprehensive resource containing spe-
cific information about best practices in instructions for
use, labelling, of RDT devices, packaging and kit accesso-
ries is not available.
In July 2012, the Diagnostics Work Stream of the Roll
Back Malaria Partnership (RBM) Procurement and Sup-
ply Chain Management Working Group commissioned
the Institute of Tropical Medicine (ITM, Antwerp,
Belgium) to assess the level of similarities and differ-
ences between current commercially available malaria
RDTs, and to identify opportunities and challenges for
enhanced and rational harmonization of malaria RDT
characteristics. As a guidance for the latter, regulatory
documents (such as legislation, regulatory guidance and
standards) and published literature relating to design,
packaging and labelling of in vitro diagnostics (IVD)
were compiled and assessed for their applicability and
feasibility to incorporate into malaria RDTs. The
process and results of these findings are described here;
the results of the comparative assessment of commer-
cially available RDTs and accessories against these find-
ings is presented elsewhere.
Methods
Working document of best practices in labelling including
instructions for use of RDTs
In a first step, regulatory guidance and guidelines for med-
ical devices were identified and assessed for applicability
for malaria RDTs. They included documents issued by the
Global Health Task Force (GHTF) (now International
Medical Device Regulators Forum (IMDRF)) [15-17],
the International Organization of Standardization (ISO
norms) [18-20], the European Commission (EC direc-
tives) [21-23], the USA Food and Drug Administration
(FDA) (http://www.fda.gov/) regulations relating to la-
belling of IVDs [24] and a the GP42-A6 guidelines (Pro-
cedures and devices for the collection of diagnostic
capillary blood specimens) from the Clinical and Labora-
tory Standards Institute (CLSI) [25]. In addition, informa-
tion about end-user errors in RDTs and readability of
instructions was retrieved from scientific literature and
complemented with ITM field observations and com-
ments from manufacturers and implementers obtained
through face-to-face structured interviews (five manufac-
turers and 9 implementers) and an internet-based ques-
tionnaire (16 implementers).
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document compiling suggestions for consideration to-
wards enhanced harmonization and user-friendliness,
addressing issues of labelling and design and construc-
tion of RDT cassette and accessories. Interviews with
manufacturers, based on these suggestions, were con-
ducted and manufacturers rated the considerations for
relevance and feasibility for incorporation into manufac-
turing processes. Full details of methods and sources can
be retrieved on the RBM website [26].
Consultation meeting with malaria control programme
implementers, manufacturers and experts in regulatory
affairs
The same ITM working document was extensively dis-
cussed during a RBM Stakeholder Consultation meeting
(December 3rd – 5th 2013, ITM) through small group
and plenary review sessions. The meeting gathered 81
participants representing (i) country programme imple-
menters (laboratory managers from the National Malaria
Control Programmes (NMCP), laboratory experts in-
volved in RDT implementation research, n = 27), (ii) ex-
perts involved in global support to RDT implementation
(n = 16), (iii) experts in IVD regulatory matters (n = 22)
and (iv) RDT manufacturer representatives (16 partici-
pants from nine companies), involved in research and
development, quality assurance, production or business
development and with sales estimated to represent over
90% of the current public market in 2010 [27].
The meeting resulted in a consolidated list of suggested
specifications promoting harmonization and set out fur-
ther steps and timelines towards enhanced harmonization
of RDT characteristics [28]. To ensure follow-up, the
meeting endorsed the RBM Procurement and Supply
Chain Management Working Group to create an ad-hoc
taskforce and participants were invited to express their
interest to join this taskforce.
MRDT harmonization task force (HarT)
The “mRDT Harmonization Taskforce” (HarT) comprised
implementers (n = 8), manufacturers (n = 4) and regulatory
experts (n = 19); its mandate included finalization of the
suggestions for interchangeability and user-friendliness of
RDTs. Between February and June 2014, HarT refined the
priorities for labelling and IFU and delivered consensus
documents including a list of harmonized terminology and
abbreviations, specifications for labelling of RDT box, buf-
fer bottle, device packaging and accessories, as well as a
generic template for IFU.
Ethical clearance
The project was submitted to and approved by the Insti-
tutional Review Board of the Institute of Tropical Medi-
cine (851/12).Results
Working document of best practice suggestions for
labelling including IFU of malaria RDTs
Figure 1 gives an overview of regulatory documents relat-
ing to labelling and IFU for IVDs. Standards and norms,
guidelines and suggestions were assessed according to the
following subjects: general requirements, content of the
label, specific labelling of RDT box, packaging, buffer bot-
tle, cassette and accessories, and IFU. Based on their as-
sessment, the final working document included 66
suggestions of which more than two-thirds (n = 46, 70%)
were related to labelling and IFU [26]. Of these 46 sugges-
tions, 33 (71.7%) were sourced from regulatory documents
and/or published literature, another 12 were made by im-
plementers and the remaining one was made by a manu-
facturer. In interviews with manufacturers, most suggested
requirements (33/46, 72%) were scored as “highly relevant”
and “feasible to align with in the short term” (i.e. within
one year).
Outcomes of consultation with RDT implementers,
manufacturers and experts in regulatory matters
The recommendations compiled in the working docu-
ment were modified and refined during the consultation
meeting. Some implementers’ suggestions were not seen
as critical, amongst them the recommendations (i) to
use an identical lot number for box, cassette packaging
and buffer vial, (ii) to display a version number of IFU on
the RDT box or device packaging, (iii) to add a revision
history to the IFU and (iv) to affix the date of production
(except in case of national regulatory requirement). Like-
wise, the recommendations to display all essential infor-
mation (including custom/variable information) grouped
together on at least two sides of the box and to print all
text and symbols in the same direction (to facilitate visual
capture at inspection) were withdrawn as well as a mini-
mum interline space of 2 for print formatting for the IFU.
The consultation report was published on the RBM web-
site [28].
Interviews with implementers confirmed that the
plethora of RDT products was perceived as a major op-
erational problem, because of variations in test proce-
dures and because of differences in reading and
interpretation of results (e.g. the characters used for the
reading legend and for the labelling of the sample and
buffer wells).
mRDT Harmonization task force (HarT) consensus
documents
The HarT further elaborated the consultation report and
developed consensus documents for RBM, presented as
additional files herein. Additional file 1 lists the recom-
mended terms and abbreviations related to malaria RDTs,
Additional file 2 lists the recommended requirements for
Figure 1 Source of regulatory documents relating to labelling and instruction for use of in vitro diagnostic medical devices.
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and accessories. Emphasis was placed on durability (per-
manent printing or water-resistant labels lasting the life-
span of the RDT product), legibility (font size, letter type,
see Figure 2), comprehension (use of symbols) and ease of
reference (e.g. place of labelling on the box or cassette
packaging, allowing quick oversight). HarT further recom-
mended the use of the official language(s) of the country/
region of intended use (expert suggestion). In addition, it
was proposed to foresee a place for affixing the Unique
Device Identification (UDI, see Figure 1) label (expert sug-
gestion). Among the information required to be displayed,
a meaningful product name (revealing the intended use
and antigens targeted) was recommended and (as forother RDT components), the expression of the expiry date
was agreed as year and month (YYYY-MM). The informa-
tion identifying the legal manufacturer should include the
name, the physical address of the manufacturing site and
contact details, i.e. telephone and/or fax number and web-
site. HarT recommended also to display a clearly visible
additional warning on the RDT box in case the test pro-
cedure or IFU had changed substantially. Figure 3A and B
display examples of the required labelling of the RDT box,
including product name, product code, intended use,
number of tests, information about the manufacturer as
well as symbols addressing storage conditions, warnings
and precautions. All relevant information needed for
stock management (e.g. product identity, storage
Figure 2 Font size in the use of labelling of in-vitro diagnostics.
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played on two sides, i.e. the front side and at least one
lateral side of the RDT box, except for custom/variable
information such as lot number and expiry date which
could be (for reasons of cost) printed on only a single
side of the box (implementer suggestion).
Likewise, consensus on labelling specifications for buf-
fer bottle, cassette packaging, desiccant packaging and
accessories (specimen transfer devices, lancets, alcohol
swabs and desiccants) were compiled (Additional file 2,
Figure 4). Similar recommendations for labelling relating
to durability, legibility and user-friendliness were made.
For the cassette packaging, the consensus was to display
all standard information (name, storage, warnings and
precautions) on one side of the packaging and to display
the custom or variable information (lot number, expiry
date) on the other side; this to allow cost-effective print-
ing and processing (implementer suggestion).
For the accessories, HarT referred to the option to dis-
play the required information on the packaging of mul-
tiple devices when it is not practicable to display it on
the device itself [15,21]. Lancets and alcohol swabs are
regulated as medical devices and are to be labeled as
such; alcohol swabs are to be labeled as antiseptics (con-
tact with tissues), not as disinfectants (contact with
objects).
For labelling of the cassette, a convention for termin-
ology and orientation of labelling was agreed (Figure 5,
implementer suggestion). Prints in indelible ink are rec-
ommended over characters embossed in the cassettehousing or labels glued to the reading legend (Figure 6).
Orientation of the text should be parallel to the short axis,
and a single unequivocal reading legend should be dis-
played at the right hand side of the results window. The
product name should be printed on the distal side of the
cassette. Specimen and buffer wells should be labeled as
“1” and “2” respectively, according to the chronological
order of the procedure. Plasmodium species detected
should be displayed by the agreed abbreviation in the
reading legend (Additional file 1).
A final HarT consensus document addressed the speci-
fications for the IFU in the form of a generic template
with background information and detailed instructions
(Additional file 3). The instructions addressed the lay-out
and style and its user-friendliness (including referral to
tools for assessing readability level) as well as a referral to
relevant and updated websites and studies. Recommenda-
tions were also compiled about appropriate description of
IVD performance specifications. In addition an example
was provided of a symbol key displaying the internation-
ally recognized symbols relevant for IVDs, along with their
explanation (expert suggestion).
Discussion
Labelling assists performance, quality and safety of
in vitro diagnostic medical devices (IVDs)
Regulation of IVDs targets consistent performance and
quality of products and their safety. Best international
regulatory practice dictates that a manufacturer should
undertake an ongoing risk assessment of the IVD
AB
Figure 3 Examples of the required labelling of the RDT box. 3 A: top side, 3 B: lateral side. Labelling includes product name, product code,
intended use, number of test, information about the manufacturer, symbols addressing storage conditions, warnings and precautions. Text in
blue displays RDT product specific characteristics.
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their consequences (false or missed diagnosis, transmis-
sion of infections etc.) are identified and minimized by
appropriate design, construction and manufacturing
[17,21]. Communication of any residual risk to the user
has to be provided by labelling, which includes labels as
well as the IFU (Figure 1) [15,17]. As such, this commu-
nication includes warnings and precautions but also
statements of known test limitations.
Labelling should target the user’s profile
An explicit part of the regulatory responsibility of the
manufacturer is to align communication to the level
of the IVD user’s education, training and expertise
[15,17]. Medium, format, content, legibility and loca-
tion of the label should be appropriate for theintended user [15]. This has particular relevance when
considering the use of malaria RDTs in the private
sector, the community and home-based management
of malaria [4,29-31].
Guidelines for lay-out and readability, and the use of
internationally recognized symbols
There are no guidelines defining labelling font sizes and
styles for IVDs, but useful information can be found in
pharmaceutical guidance on labelling of medicines’ pack-
age leaflets referring to font, lay-out and style (Figure 2)
[23]. In terms of syntax, readability is expressed by so-
called reading scales such as the Flesch-Kincaid grade
which expresses the U.S. grade-level equivalence of the
skills required to read a particular document: for the
purpose of RDTs in the present setting, a grade ≤ 6 is
Figure 4 Labelling of the buffer bottles. Two common sizes of
buffer bottles, labeled according to the HarT requirements. The label
used for the large buffer bottle has a size of 4.9 cm × 3.0 cm; all
information is displayed in a font Times New Roman, size 10 points,
bold. For the small buffer bottle, a label of 4.9 cm × 2.3 cm is used.
Essential information (commercial name, buffer bottle, expiration, lot
number) is printed in Times New Roman bold, size 9 points; other
information is printed in Times New Roman bold size 7 points.
Figure 5 Conventions for terms of the cassette. This figure
considers the most common malaria RDT i.e. a three-band RDT
targeting two antigens (P. falciparum and pan-Plasmodium antigen)
in a two-step procedure (add specimen, next add buffer) with a
cassette showing separated specimen and buffer wells. The following
convention of terms is used: proximal (closest to the specimen and
buffer wells) and distal (at the end of the migration [absorption] pad).
Considering the cassette in a vertical view (with direction of the
specimen/buffer flow “upwards”), there is the right hand side and the
left hand side.
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educational materials [32,33].
In view of swift and consistent interpretation of com-
munication, the use of graphical symbols is promoted:
symbols save space, obviate the need for translations and
convey standardized and clear messages at high visual
impact and noticeability [15,20,21,34]. Symbols de-
scribed in ISO 15223 [19] may be used in CE marked
IVDs without further explanation, however, comprehen-
sion of these assumed “self-explanatory” symbols may be
poor particularly among untrained staff in resource lim-
ited settings [35]. Therefore, in addition to training and
educational outreach, adding a symbol key (i.e. a glossary
of symbols used) to the IFU is recommended, in line
with FDA recommendations [36].
Relevance for the RDT market
The malaria RDT market currently comprises a plethora
of products and manufacturers, with constant revisions
made to products in order to improve quality and per-
formance [13,14]. Although the public sector is cen-
tered around a core set of products and suppliers, this
changes over time. Products in the private sector are
more diverse and mostly not aligned with those prod-
ucts recommended by WHO and in turn, the NMCPs(Availability and price of malaria rapid diagnostic tests
in the private health sector in 2011: results from ten na-
tionally representative cross-sectional retail surveys.
Poyer S., Goodman C et al., personal communication,
[5]). Lack of quality has been noted as an important
market shortcoming: the RDT market has started in an
era with minimal regulatory oversight or quality stan-
dards and most resource limited settings have no effect-
ive IVD regulations or post-market surveillance in place
[5]. Despite quality initiatives such as the WHO Malaria
RDT Product Testing [37] and WHO-FIND Lot Testing
Programmes [38] the WHO RDT Procurement Guidance
[14] and the WHO Prequalification of Diagnostics and
Medical Devices Programme [39], the RDT market is
Figure 6 Malaria RDT cassettes: differences in visibility between embossed versus printed characters. The figures demonstrate the
difference between visibility/readibility of embossed versus printed characters. A shows the cassettes in tangential (“side”) light: the embossed
characters are well discernable. B shows the cassettes in regular (direct) light: the embossed characters are less discernable – visibility will even
decrease in low light conditions.
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benefit margins have declined over recent years and high
orders, short lead times and an unpredictable market may
compromise product quality [5].
Another perceived difficulty of RDT use was confirmed
by interviews with implementers from the public sector in
the present study but also recorded from the private sector
[40]: weaknesses referred to aspects of labelling and IFU,
as well as RDTaccessories (lancets, alcohol swabs and spe-
cimen transfer devices). Differences in these aspects con-
tribute to the difficulties encountered in changing from
one RDT product to another, a practice dictated by the
open competitive tenders in the RDT market [5].
The present study assessed the available evidence to
identify best practices in labelling and IFUs tailored to
malaria RDTs and associated accessories. In the initial
phases of the project, identifying a representative group
of implementers involved in daily use of RDTs waschallenging; however, the consultation on the original
working document [26] and subsequent iterative review
processes gradually included a large number of partici-
pants whose activities and roles are highly related to mal-
aria RDTs use in the field, as well as their manufacturing,
their procurement and use, and their regulation. Should
this set of recommendations, most of which are derived
from existing international guidelines, be adopted broadly,
it is expected to make RDTs more user friendly and to fa-
cilitate product interchangeability. Moreover they may
contribute to increased quality and improved perform-
ance of RDTs. Based on the information of participating
manufacturers, most – if not all – recommendations
can be achieved at a reasonable cost and in a short time
span. In addition to producing a meaningful list of rec-
ommendations and reference documents, this study has
also stimulated the dialogue between users, implemen-
ters, buyers, regulatory experts and manufacturers. The
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process steered by RBM [28], may also be of value to
rapid diagnostic tests and IVDs addressing other infec-
tious diseases which is relevant since most manufac-
turers have RDTs in their portfolio specific for multiple
diseases.
The way forward, benefits of harmonization/labelling
The present HarT recommendations offer an opportun-
ity for improving consistency and harmonization of
RDT product characteristics and provide a comprehen-
sive resource upon which international recommenda-
tions and tender specifications can be based. Various
channels may be exploited for diffusion and application
to ensure maximum uptake. Furthermore, the recom-
mendations may also guide and orient emerging na-
tional IVD regulations and regional initiatives such as
the Pan-African Harmonization Working Party on
Medical Devices and Diagnostics (PAHWP) [41]. Synergis-
tic integration of the recommendations into assessment
procedures and procurement practices – particularly when
extended to other IVDs - will add quality as a driving mar-
ket factor, increase awareness about quality standards for
IVDs among end-users and provide incentives to manu-
facturers to further invest in robust quality systems.
Conclusions
The present document together with its additional files
compiled proposes best practices in labelling and IFU
for malaria RDTs. It is expected that compliance with
these best practices will increase harmonization among
the different malaria RDT products available on the
market and improve their user-friendliness.
Additional files
Additional file 1: Suggested terms and abbreviations related to
malaria RDTs.
Additional file 2: Requirements for the labelling of malaria RDT kit
components: box, cassette packaging, cassette, buffer bottle and
accessories.
Additional file 3: Generic template for Instructions for Use (IFU).
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